Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 2/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.42 |
| ▸ | BRD4 | O60885 | 3/20 | 0.42 |
| ▸ | MAP4K1 | Q92918 | 3/20 | 0.42 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.42 |
| ▸ | DCLK1 | O15075 | 2/20 | 0.41 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 9/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30878843 | 0.93 | BTK (0.47) | LRRK2BRD4MAP4K1DCLK1MAPK7 | |
| SCHEMBL30878664 | 0.90 | MAP4K1 (0.51) | LRRK2MAP4K1ALKEGFRBTK | |
| SCHEMBL30878864 | 0.89 | MAP4K1 (0.50) | FLT3LRRK2MAP4K1ALKEGFR | |
| SCHEMBL30878675 | 0.88 | MAP4K1 (0.48) | FLT3LRRK2MAP4K1ALKEGFR | |
| SCHEMBL30878814 | 0.88 | FLT3 (0.47) | FLT3MAP4K1ALKEGFRBTK | |
| SCHEMBL30878336 | 0.87 | FLT3 (0.51) | FLT3LRRK2BRD4MAP4K1MAPK3 | |
| SCHEMBL30878733 | 0.87 | FLT3 (0.48) | FLT3MAP4K1EGFRBTK | |
| SCHEMBL30878716 | 0.87 | FLT3 (0.48) | FLT3MAP4K1EGFRBTK | |
| SCHEMBL30879087 | 0.85 | ZAP70 (0.44) | LRRK2MAP4K1ALKEGFRBTK | |
| SCHEMBL30879114 | 0.85 | BTK (0.56) | FLT3EGFRBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4612148-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | Cancer Research Technology Limited (GB) | 2025-09-10 | — | — | EP | disclosed |
| WO-2024094963-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-05-10 | — | — | WO | disclosed |